Orelabrutinib plus Pola-R-CHP for untreated non-GCB DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of targeted therapy (Orelabrutinib) plus standard chemotherapy (Pola-R-CHP) for people with untreated non-GCB diffuse large B-cell lymphoma. The goal is to see if this new mix works better than the usual treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need to be between 18 and 80 years old.
- You must have a type of DLBCL called 'non-GCB' (confirmed by a biopsy).
- You should have at least one tumor that can be measured on a scan.
- You cannot have received any prior treatment for your lymphoma.
- You must be in generally good health (able to do daily activities, with adequate organ function).
- You cannot have lymphoma that has spread to your brain or spinal cord, or have an active hepatitis B or C infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of five drugs (including a targeted therapy called polatuzumab vedotin) for patients with a specific type of aggressive lymphoma (DLBCL) that has never been treated before. The goal is to see if this combination works better and is safe for certain subtypes of this cancer.
This trial tests a targeted therapy designed to match the specific genetic subtype of DLBCL that has a TP53 mutation. It may offer a more effective treatment option for people whose cancer has this genetic change.
This trial tests whether adding a targeted therapy called orelabrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of fast-growing lymphoma (CD5-positive DLBCL). If you have this lymphoma and haven't had a BTK inhibitor before, this combination might work better than chemo alone.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This trial tests a new combination of drugs for a certain type of lymphoma (non-GCB DLBCL). The drugs are pirtobrutinib (a targeted pill) plus a standard chemotherapy regimen called Pola-R-CHP. The goal is to see if adding this targeted therapy improves outcomes for people with this specific subtype.
This trial tests a combination of targeted therapy (orelabrutinib) plus chemotherapy (BR) or antibody therapy (G) for people with untreated marginal zone lymphoma. It aims to see if this combination can help patients who haven't had treatment yet.
Hear when a new Diffuse Large B-Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.